Skip to main content

Table 1 Clinicopathologic correlation of p-mTOR expression in gastric cancer

From: Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

Factors All patients No. of patients (%) P
  N= 181(%) mTOR negative mTOR positive  
Age(y)     .256
< 60 95(52.5) 50(56.8) 45(48.4)  
≥60 86(47.5) 38(43.2) 48(51.6)  
Sex     .926
Male 129(71.3) 63(71.6) 66(71.0)  
Female 52(28.7) 25(28.4) 27(29.0)  
Site     .053
Upper 77(42.5) 33(37.5) 44(47.3)  
Middle 28(15.5) 10(11.4) 18(19.4)  
lower 74(40.9) 43(48.9) 31(33.3)  
Diffuse 2(1.1) 2(2.3) 0(0.0)  
Tumor size     .172
≤ 4 cm 63(34.8) 35(40.0) 28(30.1)  
> 4 cm 118(65.2) 53(60.0) 65(69.9)  
Borrmann type     .398
Early stage 7(3.9) 6(6.8) 1(1.1)  
I 4(2.2) 2(2.3) 2(2.1)  
II 65(35.9) 31(35.2) 34(36.6)  
III 101(55.8) 47(53.4) 54(58.1)  
IV 4(2.2) 2(2.3) 2(2.1)  
grading     .999
1 4(2.2) 2(2.3) 2(2.1)  
2 55(30.4) 27(30.7) 28(30.1)  
3 116(64.1) 56(63.6) 60(64.5)  
4 6(3.3) 3(3.4) 3(3.3)  
Pathologic T classification     .168
T1 17(9.4) 12(13.6) 5(5.4)  
T2 35(19.3) 18(20.5) 17(18.3)  
T3 119(65.7) 55(62.5) 64(68.8)  
T4 10(5.5) 3(3.4) 7(7.5)  
Pathologic N status     .008
N negative 44(24.3) 29(33.0) 15(16.1)  
N positive 137(75.7) 59(67.0) 78(83.9)  
Pathologic stage (pTNM)     .026
I 26(14.4) 17(19.3) 9(9.7)  
II 47(26.0) 28(31.8) 19(20.4)  
III 100(55.2) 41(46.5) 59(63.4)  
IV 8(4.4) 2(2.3) 6(6.5)